{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:35:31Z","timestamp":1791995731350,"version":"4.4.0"},"reference-count":18,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":440,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Fine-needle aspiration (FNA) cytological analysis fails to confirm the benignity or malignancy of Bethesda III, IV and V thyroid nodules. Molecular tests performed on FNA samples have demonstrated interesting results in improving the diagnosis of these nodules. The aim of this study was to assess the performance of a large next-generation sequencing (NGS) panel in thyroid nodules with indeterminate cytology (Bethesda III, IV and V).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, monocentric study including 121 patients with cytologically indeterminate thyroid nodules (Bethesda III, IV and V) who underwent a routine FNA procedure for molecular testing using the AmpliSeq general cancer NGS panel, with an available final histological diagnosis. The main objective was to estimate the negative predictive value (NPV) of malignancy of the AmpliSeq panel in Bethesda III and IV thyroid nodules. Performance assessment (sensitivity, specificity, positive predictive value (PPV) and NPV) was carried out in the grouped categories III and IV, in the overall cohort and in each Bethesda category. The final histological diagnosis was used as the designated gold standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Histologically, 86 nodules were benign and 35 nodules were malignant. Molecular analysis yielded a positive result in 40 nodules. Panel performances assessed in the grouped categories Bethesda III and IV demonstrated a 55.0% (95% CI: 31.5; 76.9) sensitivity, a 76.9% (95% CI: 66.0; 85.7) specificity, a 37.9% (95% CI: 25.7; 51.9) PPV and an 87.0% (95% CI: 80.2; 91.7) NPV, considering a 20% prevalence of malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The performances of the AmpliSeq panel are promising; however, the NPV is not sufficient to avoid diagnostic surgery in cytologically indeterminate thyroid nodules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance statement<\/jats:title>\n                    <jats:p>Different ancillary molecular tests have been marketed in the USA and are integrated into the management of thyroid nodules with indeterminate cytology. Unfortunately, none of these molecular tests are currently available in France and clinicians lack effective tools for the management of these nodules. The aim of this work was to assess the performance of a large general-cancer targeted NGS panel in a series of thyroid nodules with indeterminate cytology (i.e. Bethesda III and IV categories and, to some extent, the Bethesda V category), managed in a French university medical center referral for thyroid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0160","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:06:23Z","timestamp":1733407583000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":3,"title":["Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7247-0267","authenticated-orcid":true,"given":"Wiame","family":"Potonnier","sequence":"first","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019Anatomie et de Cytologie Pathologiques, Sorbonne Universit\u00e9 1 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erell","family":"Guillerm","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de G\u00e9n\u00e9tique, Unit\u00e9 fonctionnelle d\u2019Oncog\u00e9n\u00e9tique et Angiog\u00e9n\u00e9tique Mol\u00e9culaire, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 2 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Bigorgne","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019Anatomie et de Cytologie Pathologiques, Sorbonne Universit\u00e9 1 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Ghander","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Pathologies Thyro\u00efdiennes et Tumorales Endocrines, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 3 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malanie","family":"Roy","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Pathologies Thyro\u00efdiennes et Tumorales Endocrines, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 3 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coulet","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de G\u00e9n\u00e9tique, Unit\u00e9 fonctionnelle d\u2019Oncog\u00e9n\u00e9tique et Angiog\u00e9n\u00e9tique Mol\u00e9culaire, Sorbonne Universit\u00e9 4 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ansart","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Pathologies Thyro\u00efdiennes et Tumorales Endocrines, Sorbonne Universit\u00e9 5 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Menegaux","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Chirurgie G\u00e9n\u00e9rale, Visc\u00e9rale et Endocrinienne, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 6 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Leenhardt","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Pathologies Thyro\u00efdiennes et Tumorales Endocrines, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 3 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brocheriou","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019Anatomie et de Cytologie Pathologiques, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 7 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Deniziaut","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019Anatomie et de Cytologie Pathologiques, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes 7 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Buffet","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Pathologies Thyro\u00efdiennes et Tumorales Endocrines, Sorbonne Universit\u00e9, GRC no. 16 Tumeurs Thyro\u00efdiennes, CNRS UMR 7371, INSERM U1146, Laboratoire d\u2019Imagerie Biom\u00e9dicale (LIB) 8 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2026070712554110600_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nrendo.2016.110","article-title":"The changing incidence of thyroid cancer","volume":"12","author":"Kitahara","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2026070712554110600_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncy.22228","article-title":"Differences in surgical resection rate and risk of malignancy in thyroid cytopathology practice between Western and Asian countries: a systematic review and meta-analysis","volume":"128","author":"Vuong","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"2026070712554110600_bib3","first-page":"1039","article-title":"The 2023 Bethesda system for reporting thyroid cytopathology","volume":"33","author":"Ali","year":"2023","journal-title":"Thyroid"},{"key":"2026070712554110600_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3892\/or.2015.4466","article-title":"An integrated analysis of cancer genes in thyroid cancer","volume":"35","author":"Chai","year":"2016","journal-title":"Oncol Rep"},{"key":"2026070712554110600_bib5","doi-asserted-by":"crossref","first-page":"649522","DOI":"10.3389\/fendo.2021.649522","article-title":"Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis","volume":"12","author":"Silaghi","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070712554110600_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5858\/arpa.2017-0174-RA","article-title":"Update on molecular testing for cytologically indeterminate thyroid nodules","volume":"142","author":"Nishino","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2026070712554110600_bib7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1002\/cncr.29038","article-title":"Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm\/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay","volume":"120","author":"Nikiforov","year":"2014","journal-title":"Cancer"},{"key":"2026070712554110600_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"2026070712554110600_bib9","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer"},{"key":"2026070712554110600_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/cncy.22112","article-title":"Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology","volume":"127","author":"Nikiforov","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"2026070712554110600_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070712554110600_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ando.2022.10.006","article-title":"SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: role of molecular tests for cytologically indeterminate thyroid nodules","volume":"83","author":"Lasolle","year":"2022","journal-title":"Ann Endocrinol"},{"key":"2026070712554110600_bib13","volume-title":"WHO Classification of TumoursOnline. Endocrine and Neuroendocrine Tumours","author":"Asa","edition":"5th ed"},{"key":"2026070712554110600_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026070712554110600_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070712554110600_bib16","doi-asserted-by":"crossref","first-page":"e230164","DOI":"10.1530\/ETJ-23-0164","article-title":"Next-generation-sequencing on fine needle aspirates in neck recurrence of thyroid cancers","volume":"13","author":"Theodon","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070712554110600_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1089\/thy.2021.0119","article-title":"Do ultrasound patterns and clinical parameters inform the probability of thyroid cancer predicted by molecular testing in nodules with indeterminate cytology?","volume":"31","author":"Figge","year":"2021","journal-title":"Thyroid"},{"key":"2026070712554110600_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncy.21356","article-title":"Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples","volume":"122","author":"Dyhdalo","year":"2014","journal-title":"Cancer Cytopathol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/1\/ETJ-24-0160.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/1\/ETJ-24-0160.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0160\/34188\/etj-24-0160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0160\/34188\/etj-24-0160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:23:53Z","timestamp":1783445033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/1\/e240160\/4622\/Performance-of-the-AmpliSeq-NGS-panel-in-thyroid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0160","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"article-number":"e240160"}}